Pharma Pricing and Market Access 2019 Day 1

08:30

Registration & refreshments

Sheela Upadhyaya
09:00

Overview of the rare diseases landscape and the challenges facing HTAs

Daniel Jackson
09:20

How to capture and quantify patient value within a commercial strategy

Luc Boileau
10:00

What is going on in Quebec about Market Access?

  • Examining Quebec life sciences strategy: Integration of medicines and technological innovations
  • Achieving cost reduction and improving access to medicines
  • Re-editing the evaluation process for the introduction of innovative medication and technologies
10:20

Speed Networking

10:40

Morning Refreshments

Ryan Saadi
11:20

The admission of value in the new marketplace

Abbes Cadi-Tazi
11:40

Biosimilars Pricing and access expectations in Europe

round tables
12:00

25 Roundtables (max 15 PAX)

Roundtable 12: Making sustainable healthcare work
Michael Schroter

Michael Schroter, Partner, Viopas Partners

Roundtable 13: “Pricing Strategy – What to Do and When?”
Andreia Ribeiro

Andreia Ribeiro, Engagement Manager, Lifescience Dynamics Ltd

Roundtable 15: Price Negotiations with Payors in Ireland & the UK
Brenda Dooley

Brenda Dooley, Founder & CEO, Axis Consulting

Roundtable 16: Phase III studies and HTA- or bringing HTA requirement in the development programs
Friedhelm Leverkus

Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer

Roundtable 18: Room At The Top? The Case For a Chief Value Officer and The Three Pillars of Responsibility: Value Communication, Value Creation and Value Governance
Don Creighton

Don Creighton, Managing Director, Huron

Roundtable 19: Shaping assets from inception to phase II to maximise pricing & market access potential
Adam Plich

Adam Plich, Former Vice President, Head Of Pricing And Market Access Europe, Teva

Roundtable 1: Bridging the gap between clinical development and medical affairs, tailoring clinical trials to meet both MA and HTA requirements
Katerina Anokhina

Katerina Anokhina, Director, Medical Affairs, Uk And Ireland, Alexion Pharma UK

Roundtable 20: Engaging with patients and improving outcomes
Dawn Ireland

Dawn Ireland, President, CDH International

Roundtable 21: Exploring role of evidence in anti-infective value assessments
Keiko Tone

Keiko Tone, VP Global Market Access, Shionogi Inc

Roundtable 23: The SmPC: friend or foe in access and pricing?
Mauricio Alvarez Reyes

Mauricio Alvarez Reyes, Market Access Expert, Independent

Roundtable 24: Exploring the landscape of drug pricing, spending and affordability in the U.S.
Robert Popovian

Robert Popovian, Vice President Of Government Relations, Pfizer

Roundtable 2: Examining emerging trends for market access in LMICs, opportunities and challenges
Hector Castro

Hector Castro, Senior Technical Director- Pharmaceutical Economics & Financing, Management Science For Health

Roundtable 3: Capability building for RWE
Elena Panitti

Elena Panitti, Global Rwe Capability Building Lead, Novartis

Roundtable 4: Payer engagement in the world of orphan drugs
Fabrizio Zucca

Fabrizio Zucca, Director Patient Access Dach, Sobi

Roundtable 8: Exploring regulatory and market access developments in advanced therapies
Renske Ten Ham

Renske Ten Ham, Phd Candidate, Utrecht University

Roundtable 9: Accelerating access to treatments for rare diseases
Nicholas Bungay

Nicholas Bungay, Director of Campaigns, Care and, Muscular Dystrophy Campaign

12:50

Networking Lunch

EVIDENCE

PRICING & MARKET ACCESS

RARE DISEASES

BIG DATA, DIGITAL HEALTH & ANALYTICS

HTA

EMERGING MARKETS

BIOSIMILARS

BIG DATA, DIGITAL HEALTH & ANALYTICS
14:10

Chair’s remarks

PRICING & MARKET ACCESS
14:15

Developments in indication and combination pricing models

  • A look at the reimbursement and pricing environment and challenges for indication-based and combination therapy pricing
  • Addressing the information gap: Infrastructure needs
  • Where are we? Case studies on indication-based and combo pricing

EVIDENCE

PRICING & MARKET ACCESS

RARE DISEASES

BIG DATA & BENEFIT ASSESSMENT

VALUE

EMERGING MARKETS AND SOUTH KOREA

BIOSIMILARS

BIG DATA, DIGITAL HEALTH & ANALYTICS
15:40

4D Insights - powering access

  • Aligning Payers, Policy Markers, Prescribers and Patient Insight using the power of Big Data
  • Real-time Insights giving competitive advantage
  • Measuring impact in real-time from within the health system
16:20

Afternoon Refreshment Break

EVIDENCE

REIMBURSEMENT

PRICING & MARKET ACCESS

RARE DISEASES

BIG DATA, DIGITAL HEALTH & ANALYTICS

EMERGING MARKETS & NEW THERAPIES

BIOSIMILARS

EMERGING MARKETS, SOUTH KOREA & JAPAN
16:50

Chair’s remarks

EVIDENCE
16:55

Use of value frameworks within oncology in Europe

  • Innovation and launches in oncology are moving at a rapid pace, potentially resulting in a delay in formal reimbursement appraisal and guidance
  • A number of value frameworks have been developed with the intent of providing rapid advice to oncologists on the clinical benefit of these new drugs
  • These value frameworks have many advantages, including clarity and brevity, but they do not replace the full value assessment of a formal HTA
RARE DISEASES
16:55

SESSION CANCELLED: (utilising disease registries for orphan drug launch)

  • Utilising disease registries is vital in rare diseases and a multicountry, multi-stakeholder approach will be discussed
  • In Europe, linkage is needed as well between registries and EU Reference networks and this can prove to be an invaluable relation ship
  • Technological challenges are a problem and potential approaches will be explored
EMERGING MARKETS, SOUTH KOREA & JAPAN
16:55

Working with stakeholders to facilitate the entry of CAR-T in Europe

Neil Mulcock, Vice President Government Affairs and Policy, Gilead Sciences
REIMBURSEMENT
17:35

Reimbursement within the world of Oncology

  • Oncology Environment and Patient Access to the Oncology Therapies
  • Patient Access & Support Programs in Oncology
  • Reimbursement issues and impact of the reimbursement delays in Oncology
last published: 18/Mar/19 14:45 GMT